Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

被引：0
|
作者：
Khan, Ali Younas [1 ]
Iftikhar, Nimra [1 ]
Ijaz, Awais [1 ]
Tariq, Muhammad Junaid [1 ]
Jamil, Faiza [1 ]
Akbar, Arshia [1 ]
Qureshi, Anum [2 ]
Jose, Jemin Aby [1 ]
Kamal, Ahmad [1 ]
Abu Zar, Muhammad [1 ]
Shafqat, Madeeha [1 ]
Selene, Insija Ilyas [1 ]
Aslam, Shehroz [1 ]
Anwer, Faiz [1 ,3 ]
机构：
[1] Univ Arizona, Div Hematol & Oncol, Dept Med, Tucson, AZ USA
[2] Univ Arizona, Div Hematol & Oncol, Dept Med, Woodbridge, VA USA
[3] Cleveland Clin, Taussig Canc Ctr, Med Oncol, Dept Hematol, Cleveland, OH 44106 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-115867
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5484
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Recent developments on JAK2 inhibitors: a patent review
    Kiss, Robert
    Sayeski, Peter P.
    Keseru, Gyoergy M.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (04) : 471 - 495
  • [22] Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
    Kalota, Anna
    Jeschke, Grace R.
    Carroll, Martin
    Hexner, Elizabeth O.
    CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1729 - 1739
  • [23] JAK2 inhibitor treatment of anemia in myelofibrosis
    Tefferi, Ayalew
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : 995 - 997
  • [24] Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
    Kalota, Anna
    Jeschke, Grace R.
    Carroll, Martin
    Hexner, Elizabeth
    BLOOD, 2011, 118 (21) : 1217 - 1217
  • [25] Treatment and management of myelofibrosis in the era of JAK inhibitors
    Keohane, Clodagh
    Radia, Deepti H.
    Harrison, Claire N.
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 189 - 198
  • [26] JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
    Wang, Xiaoli
    Ye, Fei
    Tripodi, Joseph
    Hu, Cing Siang
    Qiu, Jiajing
    Najfeld, Vesna
    Novak, Jesse
    Li, Yan
    Rampal, Raajit
    Hoffman, Ronald
    BLOOD, 2014, 124 (19) : 2987 - 2995
  • [27] JAK2 Inhibitors Do Not Affect Stem Cells Present in the Spleens of Patients with Myelofibrosis
    Wang, Xiaoli
    Tripodi, Joseph
    Novak, Jesse
    Lu, Min
    Li, Yan
    Najfeld, Vesna
    Hoffman, Ronald
    BLOOD, 2012, 120 (21)
  • [28] To Treat or Not to Treat: A Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors
    Menghrajani, Kamal
    Boonstra, Philip S.
    Weber, Alissa
    Perkins, Cecelia
    Gowin, Krisstina
    Huong Nguyen
    Mesa, Ruben
    Gotlib, Jason R.
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S236 - S236
  • [29] JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
    Santos, Fabio P. S.
    Verstovsek, Srdan
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (09) : 1098 - 1109
  • [30] Azepine inhibitors of JAK2
    Sparks, Richard B.
    Polam, Padmaja
    Arvinitis, Ari
    Rogers, James D.
    Liao, Boshan
    Covington, Maryanne
    Gallagher, Karen
    Caulder, Eian
    Shi, Jack
    Liu, Phillip C. C.
    Fridman, Jordan S.
    Scherle, Peggy A.
    Combs, Andrew P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
12345